PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19166687-1 2009 The aim of the present study was to evaluate angiographic late luminal loss after the implantation of sirolimus-eluting Cypher stents and paclitaxel-eluting Taxus stents in patients with diabetes. Sirolimus 102-111 LIM domain binding 3 Homo sapiens 120-126 19166687-11 2009 In conclusion, angiographic in-stent late luminal loss is significantly reduced in patients with diabetes by use of the sirolimus-eluting Cypher stent compared with the paclitaxel-eluting Taxus stent. Sirolimus 120-129 LIM domain binding 3 Homo sapiens 138-144 17434617-0 2008 Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "Real World"--clinical and angiographic results from the China CYPHER Select registry. Sirolimus 41-50 LIM domain binding 3 Homo sapiens 27-33 19670915-8 2009 Regarding differential efficacy of first-generation DES, a benefit may exist in favour of the Cypher (sirolimus-eluting) stent over Taxus (paclitaxel-eluting), particularly in high-risk lesion subsets. Sirolimus 102-111 LIM domain binding 3 Homo sapiens 94-100 18306306-3 2008 As a model, the CYPHER Sirolimus-eluting Coronary Stent was studied. Sirolimus 23-32 LIM domain binding 3 Homo sapiens 16-22 18510342-1 2008 Multivariate data analysis was applied to confocal Raman measurements on stents coated with the polymers and drug used in the CYPHER Sirolimus-eluting Coronary Stents. Sirolimus 133-142 LIM domain binding 3 Homo sapiens 126-132 18317669-0 2008 Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Sirolimus 38-47 LIM domain binding 3 Homo sapiens 100-106 18798379-1 2008 BACKGROUND: Although previous studies have documented persistent clinical benefit of sirolimus-eluting stents (SES)in reducing the need for target vessel revascularization without an increase in myocardial infarction (MI) or mortality, the long-term safety and efficacy of CYPHER stent use in routine clinical practice, including off-label stent implantation, remains uncertain. Sirolimus 85-94 LIM domain binding 3 Homo sapiens 273-279 17434617-1 2008 OBJECTIVE: This post-marketing surveillance registry is aimed at determining the safety and reliability of the CYPHER Select Sirolimus-eluting stent (SES) in routine clinical practice. Sirolimus 125-134 LIM domain binding 3 Homo sapiens 111-117 17876804-1 2008 Raman spectroscopy was used to differentiate each component found in the CYPHER Sirolimus-eluting Coronary Stent. Sirolimus 80-89 LIM domain binding 3 Homo sapiens 73-79 17906340-0 2007 Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. Sirolimus 11-20 LIM domain binding 3 Homo sapiens 29-35 18064507-0 2008 Sirolimus eluting stent (Cypher) in patients with diabetes mellitus: results from the German Cypher Stent Registry. Sirolimus 0-9 LIM domain binding 3 Homo sapiens 25-31 18064507-0 2008 Sirolimus eluting stent (Cypher) in patients with diabetes mellitus: results from the German Cypher Stent Registry. Sirolimus 0-9 LIM domain binding 3 Homo sapiens 93-99 17669686-0 2007 Long-term clinical follow-up of sirolimus-eluting (CYPHER) coronary stents in the treatment of instent restenosis in an unselected population. Sirolimus 32-41 LIM domain binding 3 Homo sapiens 51-57 17669686-1 2007 Randomised trials in a highly selected patient population have demonstrated a dramatic reduction in the incidence of in-stent restenosis (ISR) following implantation of sirolimus-eluting (S-E) Cypher coronary stents compared with bare metal stents (BMS). Sirolimus 169-178 LIM domain binding 3 Homo sapiens 193-199 18300741-0 2008 Higher incidence and serum levels of minor cardiac biomarker elevation in sirolimus-eluting stent (Cypher) than bare metal stent implantations. Sirolimus 74-83 LIM domain binding 3 Homo sapiens 99-105 18300741-2 2008 The sirolimus-eluting stent (Cypher) has been reported to require high postinflation pressure for optimal implantation. Sirolimus 4-13 LIM domain binding 3 Homo sapiens 29-35 16461045-0 2006 Angiographic pattern of restenosis following implantation of overlapping sirolimus-eluting (Cypher) stents. Sirolimus 73-82 LIM domain binding 3 Homo sapiens 92-98 17631219-13 2007 (RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent; http://clinicaltrials.gov/ct/show/NCT00263263?order=1; NCT00263263). Sirolimus 75-84 LIM domain binding 3 Homo sapiens 68-74 19153436-1 2007 BACKGROUND: Polymer-based sirolimus (Cypher) and paclitaxel (Taxus) drug-eluting stents (DES) have become the treatment of choice for patients with symptomatic coronary artery disease. Sirolimus 26-35 LIM domain binding 3 Homo sapiens 37-43 17379975-0 2007 Angiographic and clinical outcome following sirolimus-eluting stent (Cypher) implantation. Sirolimus 44-53 LIM domain binding 3 Homo sapiens 69-75 17969375-0 2007 Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions. Sirolimus 37-46 LIM domain binding 3 Homo sapiens 30-36 17249257-1 2006 A case of late stent occlusion of a Sirolimus eluting Cypher stent (Cordis, Johnson and Johnson) presenting as acute ST elevation myocardial infarction 22 months after deployment is reported. Sirolimus 36-45 LIM domain binding 3 Homo sapiens 54-60 17106136-0 2006 Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent. Sirolimus 19-28 LIM domain binding 3 Homo sapiens 44-50 17106136-1 2006 We estimated the benefit of a sirolimus-eluting stent (SES, Cypher) for diffuse (> 10 mm) in-stent restenosis (ISR) inside bare metal stents (BMS) because the feasibility of the SES was not confirmed after its recent approval in Japan. Sirolimus 30-39 LIM domain binding 3 Homo sapiens 60-66 16881976-3 2006 This multicenter, nonrandomized study assessed the safety and effectiveness of the CYPHER sirolimus-eluting stent in reducing angiographic in-stent late loss in totally occluded native coronary arteries. Sirolimus 90-99 LIM domain binding 3 Homo sapiens 83-89 16881976-4 2006 A total of 25 eligible patients were treated with the CYPHER sirolimus-eluting stent. Sirolimus 61-70 LIM domain binding 3 Homo sapiens 54-60 16881976-13 2006 The CYPHER sirolimus-eluting stent was safe and effective in the treatment of CTO compared to historical data with bare metal stents. Sirolimus 11-20 LIM domain binding 3 Homo sapiens 4-10 16487832-2 2006 Both DES elute compounds that inhibit the cell cycle, but at different stages: Cypher stents elute sirolimus, which induces G1 cell cycle inhibition, and Taxus stents release paclitaxel, which predominantly leads to M-phase arrest. Sirolimus 99-108 LIM domain binding 3 Homo sapiens 79-85 17700411-4 2007 We report a case in which in-stent restenosis of an overhanging stent had been treated with an also overhanging sirolimus-coated Cypher stent (Cordis Corporation, Roden, The Netherlands). Sirolimus 112-121 LIM domain binding 3 Homo sapiens 129-135 17652906-1 2007 BACKGROUND: Outcomes after sirolimus-eluting stent (SES: Cypher) implantation remained to be elucidated in Japan. Sirolimus 27-36 LIM domain binding 3 Homo sapiens 57-63 17195205-1 2007 BACKGROUND: Although the sirolimus-eluting stent (CYPHER, Cordis, USA) has shown a dramatic reduction of restenosis, there are still some concerns about its efficacy and safety. Sirolimus 25-34 LIM domain binding 3 Homo sapiens 50-56 17107279-1 2006 Cypher (sirolimus-eluting stent) and Taxus (paclitaxel-eluting stent) have been approved for use in percutaneous coronary intervention. Sirolimus 8-17 LIM domain binding 3 Homo sapiens 0-6 16864948-0 2006 Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. Sirolimus 76-85 LIM domain binding 3 Homo sapiens 101-107 16864948-1 2006 BACKGROUND: The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS). Sirolimus 98-107 LIM domain binding 3 Homo sapiens 123-129 16715886-1 2006 Drug-eluting stents (sirolimus-eluting stent: Cypher stent) have showed a reducing the frequency of in-stent restenosis and a good safety profile. Sirolimus 21-30 LIM domain binding 3 Homo sapiens 46-52 17407958-0 2006 [Use of "Cypher" sirolimus-eluting stents in coronary heart disease patients with different types of coronary arterial lesions]. Sirolimus 17-26 LIM domain binding 3 Homo sapiens 9-15 16386683-4 2006 METHODS: Reports available from April 2003 through December 2004 for hypersensitivity-like reactions associated with the sirolimus-eluting stent (CYPHER, Cordis Corp., Miami Lakes, Florida) and paclitaxel-eluting stent (TAXUS, Boston Scientific Corp., Natick, Massachusetts) were reviewed. Sirolimus 121-130 LIM domain binding 3 Homo sapiens 146-152 16273582-0 2006 Eosinophilic tissue response several weeks after sirolimus-eluting Cypher stent implantation within a bare metal stent in a coronary saphenous vein graft. Sirolimus 49-58 LIM domain binding 3 Homo sapiens 67-73 16598544-3 2006 Today, two types of drug-eluting stents are clinically used: the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus). Sirolimus 65-74 LIM domain binding 3 Homo sapiens 90-96 16461045-1 2006 Sirolimus-eluting stents (Cypher) have been shown to reduce the frequency of neointimal hyperplasia and restenosis compared with bare metal stents. Sirolimus 0-9 LIM domain binding 3 Homo sapiens 26-32 16474302-0 2006 [In-hospital and remote results of the use of sirolimus coated coronary stent CYPHER]. Sirolimus 46-55 LIM domain binding 3 Homo sapiens 78-84 16018822-1 2005 BACKGROUND: Sirolimus-eluting stents (CYPHER stents) demonstrated remarkable efficacy in reducing restenosis rates in patients with coronary artery disease. Sirolimus 12-21 LIM domain binding 3 Homo sapiens 38-44 15973656-1 2005 Sirolimus-eluting stents (SESs; Cypher) have demonstrated a significant reduction in restenosis rates when compared to bare metal stents (BMSs). Sirolimus 0-9 LIM domain binding 3 Homo sapiens 32-38 16358151-3 2005 After the administration of clopidogrel 300 mg associated with acetylsalicylic acid, the patient underwent the implantation of a sirolimus-eluting stent (CYPHER; Johnson & Johnson--Cordis) 2.5 x 1.8 mm in the lesion located at the left marginal branch. Sirolimus 129-138 LIM domain binding 3 Homo sapiens 154-160 16321180-1 2005 OBJECTIVE: To compare the short and long-term clinical outcomes of rapamycin (sirolimus)-eluting stent (DES) (CYPHER stent) and paclitaxel-DES (TAXUS stent) in treatment of coronary heart disease (CHD) patients with complicated lesions. Sirolimus 67-76 LIM domain binding 3 Homo sapiens 110-116 15737962-5 2005 The aim of this study was to evaluate the relative efficacy of sirolimus-eluting stents (Cypher) as compared with that of bare stents with thin struts (BeStent 2). Sirolimus 63-72 LIM domain binding 3 Homo sapiens 89-95 14744976-1 2004 BACKGROUND: The US Food and Drug Administration recently issued a warning of subacute thrombosis and hypersensitivity reactions to sirolimus-eluting stents (Cypher). Sirolimus 131-140 LIM domain binding 3 Homo sapiens 157-163 16243732-1 2005 OBJECTIVE: We examined our experience using the sirolimus eluting stents (Cypher) as an alternative to surgical revascularization in carefully selected cohort of patients undergoing multi-vessel percutaneous coronary intervention. Sirolimus 48-57 LIM domain binding 3 Homo sapiens 74-80 12866772-2 2003 From a recent study, the sirolimus eluting stent (SES) (CYPHER, Cordis, Johnson & Johnson) appear to demonstrate a remarkable efficacy and safety in preventing restenosis. Sirolimus 25-34 LIM domain binding 3 Homo sapiens 56-62 15029110-2 2004 This article reviews the factors previously implicated in the occurrence of stent thrombosis and analyzes recent reports of thrombosis involving a new sirolimus-eluting stent (Cypher). Sirolimus 151-160 LIM domain binding 3 Homo sapiens 176-182 23182942-0 2013 Long-term efficacy of sirolimus-eluting stent for small vessel disease--subanalysis of Cypher Stent Japan Post-Marketing Surveillance Registry. Sirolimus 22-31 LIM domain binding 3 Homo sapiens 87-93 14727933-1 2003 UNLABELLED: The sirolimus-eluting stent (CYPHER( trade mark )) is a metal stent coated with 140 micro g/cm(2) of sirolimus blended with synthetic polymers. Sirolimus 16-25 LIM domain binding 3 Homo sapiens 41-47 14727933-1 2003 UNLABELLED: The sirolimus-eluting stent (CYPHER( trade mark )) is a metal stent coated with 140 micro g/cm(2) of sirolimus blended with synthetic polymers. Sirolimus 113-122 LIM domain binding 3 Homo sapiens 41-47 30938569-0 2020 Serial optical coherence tomography and angioscopic assessments of 10-year in-stent restenosis of Cypher sirolimus-eluting stent treated with drug-coated balloon angioplasty. Sirolimus 105-114 LIM domain binding 3 Homo sapiens 98-104 26875959-1 2016 Drug-eluting stents (DES) are widely used for the treatment of coronary artery disease, and a sirolimus-eluting stent (SES; Cypher) was the first DES introduced into clinical practice. Sirolimus 94-103 LIM domain binding 3 Homo sapiens 124-130 28846543-1 2017 AIMS: Our aim was to report the long-term safety and efficacy of the biodegradable polymer-coated biolimus- eluting Nobori stent compared to the durable polymer-coated sirolimus-eluting CYPHER stent. Sirolimus 168-177 LIM domain binding 3 Homo sapiens 186-192 27558119-0 2017 Nine-year follow-up of progressive peri-stent contrast staining after Cypher sirolimus-eluting stent implantation: a case report. Sirolimus 77-86 LIM domain binding 3 Homo sapiens 70-76 27558119-1 2017 A 62-year-old male underwent three percutaneous coronary interventions involving four bare metal stents and six Cypher sirolimus-eluting stents within 1 month. Sirolimus 119-128 LIM domain binding 3 Homo sapiens 112-118 23996918-1 2014 OBJECTIVE: To evaluate the effects of the everolimus-eluting Xience /Promus stent (EES) and the sirolimus-eluting Cypher stent (SES) on intimal hyperplasia (IH) in diabetic patients. Sirolimus 97-106 LIM domain binding 3 Homo sapiens 115-121 24717233-3 2014 Cypher sirolimus-eluting stent has been reported to accelerate atherosclerosis progression, but the influence of Endeavor zotarolimus-eluting stent (Endeavor-ZES) or Xience everolimus-eluting stent (Xience-EES) on atherosclerosis has not been clarified. Sirolimus 7-16 LIM domain binding 3 Homo sapiens 0-6 22424016-0 2012 Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Sirolimus 90-99 LIM domain binding 3 Homo sapiens 83-89 22533814-1 2012 Drug release from and coating morphology on a CYPHER sirolimus-eluting coronary stent (SES) during in vitro elution were studied by correlated confocal Raman and atomic force microscopy (CRM and AFM, respectively). Sirolimus 53-62 LIM domain binding 3 Homo sapiens 46-52 21394029-2 2011 METHODS: We conducted a prospective 5-year clinical evaluation following implantation of sirolimus-eluting Cypher stents for in-stent restenosis regardless of the patient"s symptomatic status. Sirolimus 89-98 LIM domain binding 3 Homo sapiens 107-113 21394029-5 2011 CONCLUSION: These results, of a comparably large series, indicate that the implantation of sirolimus-eluting Cypher stents for the treatment of coronary in-stent restenosis is effective and safe and associated with a stable clinical course in the very long term. Sirolimus 91-100 LIM domain binding 3 Homo sapiens 109-115 21251624-0 2011 Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). Sirolimus 70-79 LIM domain binding 3 Homo sapiens 63-69 21251624-1 2011 OBJECTIVES: The aim of this study was to assess the long-term safety and efficacy of the CYPHER (Cordis, Johnson and Johnson, Bridgewater, New Jersey) sirolimus-eluting coronary stent (SES) in percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Sirolimus 151-160 LIM domain binding 3 Homo sapiens 89-95 19858414-0 2009 Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry. Sirolimus 26-35 LIM domain binding 3 Homo sapiens 134-140 20405134-2 2010 The aim of our study was to compare the tacrolimus-eluting carbon-coated JANUS( ) stent with sirolimus-eluting CYPHER( ) stent for the prevention of symptom-driven clinical end points in a real world clinical setting. Sirolimus 93-102 LIM domain binding 3 Homo sapiens 111-117 22187903-0 2010 [Long-term follow-up use of "cypher" sirolimus-eluting stents in patients with coronary heart disease after coronary artery bypass grafting with occlusive lesions of the coronary artery]. Sirolimus 37-46 LIM domain binding 3 Homo sapiens 29-35 20542782-2 2010 We evaluated the HRQL following sirolimus-eluting coronary stent (SES) (CYPHER(R); Cordis, Johnson & Johnson, Warren, NJ, USA) implantation in patients with multivessel disease, comparing the outcomes with the historical surgical and bare metal stent (BMS) arms of the ARTS-I study. Sirolimus 32-41 LIM domain binding 3 Homo sapiens 72-78 19858414-2 2009 METHODS AND RESULTS: j-Cypher is a multicenter prospective registry of consecutive patients undergoing sirolimus-eluting stent implantation in Japan. Sirolimus 103-112 LIM domain binding 3 Homo sapiens 23-29 19564562-1 2009 BACKGROUND: Although both sirolimus (CYPHER) and paclitaxel (TAXUS) drug-eluting stents have demonstrated efficacy and safety in clinical trials, human autopsy data have raised concerns about long-term healing and the potential for local inflammatory reactions. Sirolimus 26-35 LIM domain binding 3 Homo sapiens 37-43 19406341-10 2009 The Endeavor stent and the sirolimus-eluting Cypher stent (Cordis, Johnson & Johnson, Miami, Florida) had higher restenosis rates in patients with DM compared with those in patients without DM (RR: 1.77, 95% CI: 1.29 to 2.43 and RR: 1.25, 95% CI: 1.04 to 1.51). Sirolimus 27-36 LIM domain binding 3 Homo sapiens 45-51